Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANG-3070 in primary glomerular disease
NCT04939116Phase 2Unknown
- Sponsor
- Angion Biomedica Corp.
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ansornitinib in primary glomerular disease (4 arms), sponsored by Angion Biomedica Corp. Primary endpoint: Percentage change in 24-hour urinary protein excretion at 12 weeks. Status: unknown.
02
Drugs
ansornitinib
03
Conditions
primary glomerular disease
Beyond the preview
Go deeper on NCT04939116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939116.